Trials / Unknown
UnknownNCT02799680
Allogeneic CART-33 for Relapsed/Refractory CD33+ AML
Treatment of Relapsed and/or Refractory CD33-positive Acute Myeloid Leukemia by Infusions of Allogeneic CART-33
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 12 (estimated)
- Sponsor
- The Affiliated Hospital of the Chinese Academy of Military Medical Sciences · Academic / Other
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and efficiency of allogeneic cluster of differentiation 33 (CD33)-directed chimeric antigen receptor modified T cells (CART-33) infusions in patients with relapsed / refractory acute myeloid leukemia (AML).
Detailed description
The relapsed and/or refractory AML patients will receive infusions of allogeneic CART-33 within 1 week after chemotherapy. The re-induction chemotherapy regimen was primarily idarubicin and cytarabine, and no graft-versus-host disease (GVHD) prevention was conducted pre- and post- therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | allogeneic CART-33 | allogeneic CD33-directed chimeric antigen receptor-modified T cells (CART-33) |
Timeline
- Start date
- 2015-10-01
- Primary completion
- 2017-05-01
- Completion
- 2018-05-01
- First posted
- 2016-06-15
- Last updated
- 2016-06-15
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT02799680. Inclusion in this directory is not an endorsement.